3-[(6-aminohexanoyl)ethoxycarbonylmethylamino]propionic acid ethyl ester hydrochloride | 786681-43-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-[(6-aminohexanoyl)ethoxycarbonylmethylamino]propionic acid ethyl ester hydrochloride
• 英文别名: Ethyl 3-[6-aminohexanoyl-(2-ethoxy-2-oxoethyl)amino]propanoate;hydrochloride
• CAS: 786681-43-4
• 化学式: C₁₅H₂₈N₂O₅*ClH
• 分子量: 352.859
• InChiKey: BEJYOUOIWCGKSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.27
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  98.9
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-[(6-aminohexanoyl)ethoxycarbonylmethylamino]propionic acid ethyl ester hydrochloride 在 吡啶 、 甲醇 、 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 potassium tert-butylate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 18.83h， 生成 succinic acid mono-(4-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-1-{6-[17-(1,5-dimethyl-hexyl)-10,13-dimethyl 2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H cyclopenta[a]phenanthren3-yloxycarbonylamino]-hexanoyl}-pyrrolidin-3-yl)ester
  参考文献：
  名称：

  Compositions and methods for inhibiting expression of an RNA from west nile virus

  摘要：

  这项发明涉及双链核糖核酸（dsRNA），以及其在介导RNA干扰中抑制西尼罗病毒（WNV）的RNA表达方面的应用，以及利用dsRNA治疗由WNV感染介导的病理过程，如病毒性脑炎。

  公开号：

  US09200282B2
• 作为产物：
  描述：

  3-[(6-amino-hexanoyl)(ethoxycarbonylmethyl)amino]-propionic acid ethyl ester 生成 3-[(6-aminohexanoyl)ethoxycarbonylmethylamino]propionic acid ethyl ester hydrochloride
  参考文献：
  名称：

  [EN] NUCLEASE RESISTANT DOUBLE-STRANDED RIBONUCLEIC ACID
  [FR] ACIDE RIBONUCLEIQUE DOUBLE BRIN RESISTANT AUX NUCLEASES

  摘要：

  公开号：

  WO2005115481A3

文献信息

• Compositions and methods for inhibiting expression of Nav1.8 gene
  申请人：Sah Dinah

  公开号：US20070105806A1

  公开（公告）日：2007-05-10

  The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell.

  该发明涉及一种双链核糖核酸(dsRNA)，用于抑制Nav1.8基因(Nav1.8基因)的表达，包括具有核苷酸序列的反义链，其长度小于25个核苷酸，并且与Nav1.8基因的至少一部分基本互补。该发明还涉及包括dsRNA和药用可接受载体的药物组合物；使用该药物组合物治疗由Nav1.8基因表达引起的疾病的方法；以及在细胞中抑制Nav1.8基因表达的方法。
• COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A GENE FROM THE EBOLA
  申请人：Bavari Sina

  公开号：US20090143323A1

  公开（公告）日：2009-06-04

  The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.

  这项发明涉及一种用于抑制埃博拉病毒基因表达的双链核糖核酸(dsRNA)。
• Compositions and methods for inhibiting expression of the PCSK9 gene
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US07605251B2

  公开（公告）日：2009-10-20

  The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the proprotein convertase subtilisin kexin 9 (PCSK9) gene, comprising an antisense strand having a nucleotide sequence which is less than 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; and methods for treating diseases caused by PCSK9 gene expression by using the pharmaceutical composition.

  该发明涉及一种双链核糖核酸(dsRNA)，用于抑制前蛋白酶转化亚硫酸酯基肽酶9 (PCSK9) 基因的表达，包括具有核苷酸序列的反义链，其长度小于30个核苷酸，通常为19-25个核苷酸，并且与PCSK9基因的至少一部分基本互补。该发明还涉及包括dsRNA和药学上可接受的载体的药物组合物；以及使用该药物组合物治疗由PCSK9基因表达引起的疾病的方法。
• Lipid Formulated Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20150353934A1

  公开（公告）日：2015-12-10

  The invention relates to lipid formulated double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.

  该发明涉及脂质配方的双链核糖核酸(dsRNA)，用于抑制埃博拉病毒基因的表达。
• COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 GENE
  申请人：Bumcrot David

  公开号：US20070281899A1

  公开（公告）日：2007-12-06

  The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.

  该发明涉及一种双链核糖核酸（dsRNA），用于抑制Eg5基因（Eg5基因）的表达，包括具有核苷酸序列的反义链，其长度不超过30个核苷酸，通常为19-25个核苷酸，并且与Eg5基因的至少一部分基本互补。该发明还涉及一种含有dsRNA和药用载体的药物组合物；使用该药物组合物治疗由Eg5表达和Eg5基因表达引起的疾病的方法；以及在细胞中抑制Eg5基因表达的方法。